Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (201-210 of 353) with videos related to

Pageof 36
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|February 18, 2003
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis modelKai Wang, Xiaorong Zhou, Zhongmin Zhou, et al.
Thrombosis and Haemostasis|August 3, 2002
Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusionKai Wang, Xiaorong Zhou, Zhongmin Zhou, et al.
Journal of the American Heart Association|November 23, 2019
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE TrialAnirudh Kumar, Divyang R Patel, Danielle M Brennan, et al.
American Heart Journal|September 29, 2014
Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary interventionAkshay Bagai, Phillip J Schulte, Christopher B Granger, et al.
JAMA Cardiology|March 12, 2018
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control StudySteven E Nissen, Sreekumar G Pillai, Stephen J Nicholls, et al.
The American Journal of Medicine|July 31, 2017
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION TrialDaniel H Solomon, M Elaine Husni, Peter A Libby, et al.
The Journal of Invasive Cardiology|June 30, 2015
Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Treatment in Patients With Acute Coronary Syndrome: Analysis From the ACUITY TrialMarco G Mennuni, George D Dangas, Roxana Mehran, et al.
Plos One|November 15, 2022
Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazarEsmée J Grobbee, Vivian D de Jong, Ilse C Schrieks, et al.
Endocrine Connections|March 9, 2026
Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UKThomas van Sloten, Steven H J Hageman, Jan Westerink, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 2, 2015
Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trialsJennifer Yu, Roxana Mehran, Tim Clayton, et al.
Pageof 36

Showing results (201-210 of 353) with videos related to

Sort By:
Pageof 36
Arteriosclerosis, Thrombosis, and Vascular Biology|February 18, 2003
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis modelKai Wang, Xiaorong Zhou, Zhongmin Zhou, et al.
Thrombosis and Haemostasis|August 3, 2002
Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusionKai Wang, Xiaorong Zhou, Zhongmin Zhou, et al.
Journal of the American Heart Association|November 23, 2019
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE TrialAnirudh Kumar, Divyang R Patel, Danielle M Brennan, et al.
American Heart Journal|September 29, 2014
Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary interventionAkshay Bagai, Phillip J Schulte, Christopher B Granger, et al.
JAMA Cardiology|March 12, 2018
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control StudySteven E Nissen, Sreekumar G Pillai, Stephen J Nicholls, et al.
The American Journal of Medicine|July 31, 2017
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION TrialDaniel H Solomon, M Elaine Husni, Peter A Libby, et al.
The Journal of Invasive Cardiology|June 30, 2015
Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Treatment in Patients With Acute Coronary Syndrome: Analysis From the ACUITY TrialMarco G Mennuni, George D Dangas, Roxana Mehran, et al.
Plos One|November 15, 2022
Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazarEsmée J Grobbee, Vivian D de Jong, Ilse C Schrieks, et al.
Endocrine Connections|March 9, 2026
Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UKThomas van Sloten, Steven H J Hageman, Jan Westerink, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 2, 2015
Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trialsJennifer Yu, Roxana Mehran, Tim Clayton, et al.
Pageof 36